West Pharmaceutical Services (WPS) Stock Forecast & Price Target
WPS Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to West Pharmaceutical Services in the past 3 months
WPS Stock 12 Month Forecast
Average Price Target
EUR 428.15▲(12.55% Upside)Based on 6 Wall Street analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is EUR 428.15 with a high forecast of EUR 447.70 and a low forecast of EUR 358.16. The average price target represents a 12.55% change from the last price of EUR 380.40.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 447.70
AverageEUR 428.15
LowEUR 358.16
Highest Price TargetHighestEUR 447.70Average Price TargetEUR 428.15Lowest Price TargetLowestEUR 358.16
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | Barclays | EUR 393.98→EUR 447.70 | buy | 17.69%Upside | Reiterated | 10/30/26 | ||
| Joanne Wuensch | Citi | EUR 368.90→EUR 442.33 | buy | 16.28%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | UBS | EUR 389.50→EUR 443.22 | buy | 16.51%Upside | Reiterated | 10/30/26 | ||
| Daniel Markowitz CFA | Evercore ISI | EUR 393.98→EUR 429.79 | buy | 12.98%Upside | Reiterated | 10/30/26 | ||
| Brendan Smith | TD Cowen | EUR 376.07→EUR 447.70 | buy | 17.69%Upside | Reiterated | 10/29/26 | ||
| Kallum Titchmarsh | Morgan Stanley | EUR 326.82→EUR 358.16 | buy | -5.85%Downside | Upgraded | 09/22/26 | ||
| Michael Ryskin | Bank of America Securities | EUR 367.11 | buy | -3.49%Downside | Reiterated | 07/24/26 | ||
| Matt Larew | William Blair | ― | buy | ― | Reiterated | 07/23/26 | ||
| Curtis Moiles | Exane BNP Paribas | EUR 400.24 | buy | 5.22%Upside | Initiated | 07/13/26 | ||
| Paul Knight | KeyBanc | EUR 313.39→EUR 349.21 | buy | -8.20%Downside | Reiterated | 07/02/26 | ||
| Michael Polark | Wolfe Research | EUR 335.77 | buy | -11.73%Downside | Assigned | 06/01/26 | ||
| Justin Bowers | Deutsche Bank | EUR 277.57→EUR 282.05 | buy | -25.85%Downside | Reiterated | 02/13/26 | ||
| Dan Leonard | RBC Capital | EUR 317.87→EUR 304.44 | buy | -19.97%Downside | Reiterated | 02/13/26 | ||
| David Windley | Jefferies | EUR 326.82→EUR 264.14 | buy | -30.56%Downside | Reiterated | 02/10/26 | ||
| Nico Chen | DBS | EUR 286.53 | buy | -24.68%Downside | Reiterated | 01/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Luke Sergott | 10/30/26 | EUR 393.98→EUR 447.70 | buy | 17.69%Upside | Reiterated | Barclays | ||
| Joanne Wuensch | 10/30/26 | EUR 368.90→EUR 442.33 | buy | 16.28%Upside | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 10/30/26 | EUR 389.50→EUR 443.22 | buy | 16.51%Upside | Reiterated | UBS | ||
| Daniel Markowitz CFA | 10/30/26 | EUR 393.98→EUR 429.79 | buy | 12.98%Upside | Reiterated | Evercore ISI | ||
| Brendan Smith | 10/29/26 | EUR 376.07→EUR 447.70 | buy | 17.69%Upside | Reiterated | TD Cowen | ||
| Kallum Titchmarsh | 09/22/26 | EUR 326.82→EUR 358.16 | buy | -5.85%Downside | Upgraded | Morgan Stanley | ||
| Michael Ryskin | 07/24/26 | EUR 367.11 | buy | -3.49%Downside | Reiterated | Bank of America Securities | ||
| Matt Larew | 07/23/26 | ― | buy | ― | Reiterated | William Blair | ||
| Curtis Moiles | 07/13/26 | EUR 400.24 | buy | 5.22%Upside | Initiated | Exane BNP Paribas | ||
| Paul Knight | 07/02/26 | EUR 313.39→EUR 349.21 | buy | -8.20%Downside | Reiterated | KeyBanc | ||
| Michael Polark | 06/01/26 | EUR 335.77 | buy | -11.73%Downside | Assigned | Wolfe Research | ||
| Justin Bowers | 02/13/26 | EUR 277.57→EUR 282.05 | buy | -25.85%Downside | Reiterated | Deutsche Bank | ||
| Dan Leonard | 02/13/26 | EUR 317.87→EUR 304.44 | buy | -19.97%Downside | Reiterated | RBC Capital | ||
| David Windley | 02/10/26 | EUR 326.82→EUR 264.14 | buy | -30.56%Downside | Reiterated | Jefferies | ||
| Nico Chen | 01/28/26 | EUR 286.53 | buy | -24.68%Downside | Reiterated | DBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering West Pharmaceutical Services
3 Months
Success Rate8/10 ratings generated profit
80%
Average Return
+14.30%
Copying Matt Larew's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +14.30% per trade.
1 Year
Success Rate5/5 ratings generated profit
100%
Average Return
+36.08%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.08% per trade.
2 Years
Success Rate6/6 ratings generated profit
100%
Average Return
+59.88%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +59.88% per trade.
WPS Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 17 | 14 | 13 | 10 | 9 |
| Hold | 5 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 16 | 15 | 11 | 10 |
In the current month, WPS has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. WPS average Analyst price target in the past 3 months is 428.15.
WPS Financial Forecast
HighEUR 2.07
ConsensusEUR 2.04
LowEUR 1.99
WPS Earnings Forecast
Next quarter’s earnings estimate for WPS is EUR 2.04 with a range of EUR 1.99 to EUR 2.07. The previous quarter’s EPS was EUR 2.37. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 740M
ConsensusEUR 736M
LowEUR 733M
WPS Sales Forecast
Next quarter’s sales forecast for WPS is EUR 736.19M with a range of EUR 732.66M to EUR 739.81M. The previous quarter’s sales results were EUR 780.32M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
WPS Stock Forecast FAQ
What is DE:WPS’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services’s 12-month average price target is €428.15.
What is DE:WPS’s upside potential, based on the analysts’ average price target?
West Pharmaceutical Services has 12.55% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is West Pharmaceutical Services a Buy, Sell or Hold?
West Pharmaceutical Services has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is West Pharmaceutical Services’s share price target?
The average share price target for West Pharmaceutical Services is €428.15. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €447.70, and the lowest forecast is €358.16. The average share price target represents a 12.55% increase from the current price of €380.4.
What do analysts say about West Pharmaceutical Services?
West Pharmaceutical Services’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of West Pharmaceutical Services?
To buy shares of DE:WPS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
